'The most exciting company in Australia': The ASX stock up 179% in 6 months

This outfit remains a bargain despite almost tripling its share price since June, say experts.

| More on:
A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If an ASX biotech stock has almost tripled in 6 months but the valuation still remains "cheap", then you would be careless to not at least consider adding it to your portfolio.

According to Frazis Capital portfolio manager Michael Frazis, Sydney company Clarity Pharmaceuticals Ltd (ASX: CU6) has been "on a bit of a tear".

"This is the most exciting company I've come across in Australia lately," he said in a memo to clients.

"Clarity has been steadily releasing data from patients treated with their copper therapies with late stage prostate cancer."

That data has apparently been favourable, causing the share price to rocket 179% from its 52-week low in late June.

Biotechs snapped up for billions with early data

Frazis said that mergers and acquisitions activity in the global biotechnology industry has been "intense".

And those transactions provide some clues as to how undervalued Clarity Pharmaceuticals still is, despite the spectacular rise the last few months.

"If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data."

Just last week US$100 billion giant Bristol-Myers Squibb Co (NYSE: BMY) acquired RayzeBio Inc (NASDAQ: RYZB) for US$4.1 billion, on the back of early data for its gastroenteropancreatic neuroendocrine tumour therapy and the start of a phase III trial.

"And Novartis AG (SWX: NOVN) paid US$2 billion for Endocyte in late 2018 with only Phase II data," said Frazis.

"This has proved a big winner, with first year revenues for their first product Pluvicto forecast at over US$1 billion."

This week Eli Lilly And Co (NYSE: LLY) completed its acquisition of Point Biopharma Global Inc (NASDAQ: PNT) for US$1.4 billion with only phase II data.

This is why Frazis believes that the Clarity share price remains a bargain despite the massive appreciation this year.

"In a space where companies with promising data are being acquired for billions of dollars, and Clarity's early indications look best-in-class, the company's post-runup US$340 million valuation looks cheap."

'Double or even triple industry revenues'

Prostate cancer will be "a large market", according to Frazis.

"The trend is towards increased monitoring and — where possible — fewer surgeries and hormone therapy, which involves the unwelcome side effects of incontinence, impotence, low testosterone and depression."

Currently the biotechs are treating "heavily pretreated patients", but in the longer run their solutions could be applied more proactively.

"The hope is that these targeted treatments, with their milder side effects, will move further up the treatment timeline, which could double or even triple industry revenues," said Frazis.

"This will take time, given the high hurdle for changing standard-of-care, but is looking more likely than ever today."

In the short term, both incidence and diagnosis is increasing for prostate cancer, which will keep feeding Clarity's valuation.

While the biotech stock is sparsely covered, at least Jefferies and Wilsons analysts agree with Frazis. Both teams rate Clarity Pharmaceuticals as a strong buy, as shown in CMC Invest.

Should you invest $1,000 in Clarity Pharmaceuticals right now?

Before you buy Clarity Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Clarity Pharmaceuticals wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Bristol Myers Squibb and Point Biopharma Global. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Buy, hold and sell ratings written on signs on a wooden pole.
Healthcare Shares

CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

It has been a tough start to the week for this medical device company's shareholders.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

This little-known healthcare company is now the 17th-largest business in the ASX 200

This stock isn’t well-known, but it’s a market leader with significant potential.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why I think this ASX small-cap share is a buy at $1.18

After falling almost 17% over the past year, I see a lot of value at the current price.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »